The new prescription drugs from two Chinese companies may be a bargain compared to generic versions from generic drugmakers, but the two are no substitute for the real deal, the American and Japanese government’s top drug regulators have said.
The government said Thursday that the two new medicines were not cheaper than the generic versions and should be excluded from the market.
“We strongly urge all generic manufacturers to stop producing these drugs,” said the National Institute of Allergy and Infectious Diseases (NIAID), which regulates prescription drugs.
NIAid said it was concerned that the drugs were being produced at lower-cost than they should be, especially in areas where the drug is sold at higher prices.
It also said the drug makers were violating the law by not paying royalties to the U.S. government on the medicines.
There are no approved medicines for the disease, and the United States has not produced a treatment since 2004.
This year, the U